Provided by Tiger Fintech (Singapore) Pte. Ltd.

Viridian Therapeutics, Inc.

13.53
+0.03000.22%
Pre-market: 13.15-0.3800-2.81%04:07 EDT
Volume:683.51K
Turnover:9.25M
Market Cap:1.10B
PE:-4.40
High:13.96
Open:13.40
Low:13.27
Close:13.50
Loading ...

Company Profile

Company Name:
Viridian Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
2010
Employees:
143
Office Location:
221 Crescent Street,Suite 401,Waltham,Massachusetts,United States
Zip Code:
02453
Fax:
617 272 4601
Introduction:
Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-002 and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-004, a discovery-stage therapeutic antibody program for rare disease; and VRDN-005 and VRDN-006, a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. is headquartered in Waltham, Massachusetts.

Directors

Name
Position
Jonathan Violin
President, Chief Executive Officer and Director
Arlene M. Morris
Director
Peter Harwin
Director
Tomas Kiselak
Director

Shareholders

Name
Position
Jonathan Violin
President, Chief Executive Officer and Director
Jason A. Leverone
Chief Financial Officer, Treasurer, and Secretary
Barrett Katz
Chief Medical Officer